SOA101
/ Shine-On Biomedical
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
August 01, 2025
NbTAST-01: A Study to Investigate Safety and Preliminary Efficacy of SOA101 in Adult Subjects With Advanced Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=76 | Recruiting | Sponsor: Shine-On Biomedical Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Solid Tumor
July 09, 2025
NbTAST-01: A Study to Investigate Safety and Preliminary Efficacy of SOA101 in Adult Subjects With Advanced Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=76 | Not yet recruiting | Sponsor: Shine-On Biomedical Co., Ltd.
New P1/2 trial • Solid Tumor
February 05, 2025
China Medical University and Healthcare System Pioneers AI-Driven Drug Discovery and Allogeneic CAR-T Therapy: A Groundbreaking Leap in Cancer Treatment
(PRNewswire)
- "CMU and Healthcare System revealed the world's first allogeneic CAR-T therapy for solid cancers, developed by Ever Supreme Bio Technology. This therapy has demonstrated an unprecedented tumor reduction rate of over 90% in pre-clinical studies. Human clinical trials are underway, with FDA approval marking a pivotal moment in solid tumor treatment...Their innovations include: SOA101 Trispecific Antibody: A nanobody-based platform combining two immune checkpoint inhibitors, now in FDA-reviewed Phase I/IIa trials for cancer therapy; SOB100 HLA-G Targeted Exosome: Delivering drugs with pinpoint precision to tumors, this platform enhances efficacy while minimizing side effects...Human clinical trials for these technologies are set to begin in 2025..."
New trial • Preclinical • Solid Tumor
1 to 3
Of
3
Go to page
1